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Precision newborn screening for lysosomal disorders
Melissa M. Minter Baerg, MBA1, Stephanie D. Stoway, MPH1, Jeremy Hart, MD2,3, Lea Mott, MT2,
Dawn S. Peck, MS, CGC1, Stephanie L. Nett, MTASCP1, Jason S. Eckerman, BS1, Jean M. Lacey, BS1,
Coleman T. Turgeon, MS1, Dimitar Gavrilov, MD, PhD1, Devin Oglesbee, PhD1, Kimiyo Raymond, MD1,
Silvia Tortorelli, MD, PhD1, Dietrich Matern, MD, PhD1, Lars Mørkrid, MD, PhD4 and
Piero Rinaldo, MD, PhD1
Purpose: The implementation of newborn screening for lysosomal
disorders has uncovered overall poor specificity, psychosocial harm
experienced by caregivers, and costly follow-up testing of false-positive
cases. We report an informatics solution proven to minimize these issues.
Methods: The Kentucky Department for Public Health out-
sourced testing for mucopolysaccharidosis type I (MPS I) and
Pompe disease, conditions recently added to the recommended
uniform screening panel, plus Krabbe disease, which was added by
legislative mandate. A total of 55,161 specimens were collected from
infants born over 1 year starting from February 2016. Testing by
tandem mass spectrometry was integrated with multivariate pattern
recognition software (Collaborative Laboratory Integrated Reports),
which is freely available to newborn screening programs for
selection of cases for which a biochemical second-tier test is
needed.
Results: Of five presumptive positive cases, one was affected with
infantile Krabbe disease, two with Pompe disease, and one with
MPS I. The remaining case was a heterozygote for the latter
condition. The false-positive rate was 0.0018% and the positive
predictive value was 80%.
Conclusion: Postanalytical interpretive tools can drastically reduce
false-positive outcomes, with preliminary evidence of no greater
risk of false-negative events, still to be verified by long-term
surveillance.
Genet Med advance online publication 9 November 2017
Key Words: collaborative laboratory integrated report; Krabbe
disease; mucopolysaccharidosis type I; newborn screening; Pompe
disease
INTRODUCTION
Newborn screening is a public health program aimed at the
identification of conditions for which early intervention can
prevent mortality, morbidity, and disabilities,1 but is not
without its challenges.2 In recent years, expansions of testing
panels have been proposed and adopted either as national
standards3 or as nonbinding recommendations4 by the US
Department of Health and Human Services (HHS). Currently,
the recommended uniform screening panel encompasses 34
conditions. The HHS Secretary’s Advisory Committee
on Heritable Disorders in Newborns and Children is tasked
with overseeing the process5 of adding emerging conditions6,7
to the recommended panel. The most recent additions
are acid α-glucosidase (GAA) deficiency (Pompe disease),8
α-L-iduronidase (IDUA) deficiency (MPS I),9 and X-linked
adrenoleukodystrophy.10 Other lysosomal disorders, parti-
cularly galactocerebrosidase (GALC) deficiency (Krabbe
disease),11 have been turned down by the committee because
they lacked evidence of net benefits. However, advocacy
efforts and legislative mandates have propelled six states to
begin screening for Krabbe disease and other lysosomal
disorders,12–14 but reports of outcomes and performance have
not been encouraging.15–17
In 2015, the legislature of the Commonwealth of Kentucky
passed bill KRS 214.155, mandating screening for Krabbe
disease. This action was driven by an advocacy campaign led
by the parents of a child affected with the infantile form of the
disease. To accelerate implementation, the Kentucky Depart-
ment for Public Health reached out to the Biochemical
Genetics Laboratory at Mayo Clinic (Rochester, Minnesota) to
negotiate outsourcing of screening for Krabbe disease by
measuring only GALC activity. This assay had to be
performed in parallel to local testing for all other conditions
and be completed within 24 hours to avoid any further delays
in the care of early-onset cases.18 This request was not fulfilled
because conventional interpretation methods of a single
marker (cutoff, percent of daily mean) are not suited to
differentiation of affected patients from individuals who are
either heterozygous or carry pseudo-deficiency alleles.12–15
The laboratory made a counter-proposal to perform a profile
of six lysosomal enzyme activities using commercially
available substrates, inclusive of the primary markers of
Pompe disease and MPS I, integrated with additional analytes
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and second-tier tests as needed. This new plan, characterized
by the expanded scope of testing and reporting of three
conditions, was agreeable to both Kentucky and Mayo Clinic.
The solution adopted here as primary screening was to rely on
six covariate-adjusted enzyme activities integrated by all
informative permutations of calculated ratios among them.
MATERIALS AND METHODS
Reference population and patients
Supplementary Figure 1 online shows the size of the
cumulative reference population with and without covariate
(age at collection and body weight) correction for GALC
activity, which was compiled by the end of the first year of
testing. At the beginning of prospective testing, reference data
from the pilot study mentioned below were also used, but
were phased out when approximately 10,000 prospective cases
had been tested. The data sets for acid sphingomyelinase,
GAA, α-galactosidase, β-glucocerebrosidase, and IDUA were
of comparable sizes. To create postanalytical interpretive
tools, enzyme profiles of true- and false-positive cases were
available from previous clinical testing (confirmed true
positives) and unpublished research studies (presumed true
positives). Confirmed true positives were all proven by
genotyping to carry known pathogenic variants in trans but
were not sorted by predicted genotype–phenotype correlation.
Cases categorized as presumed false positives were either
heterozygous for pathogenic variants or carrying known
pseudodeficiency alleles. With approval from the Mayo
Clinic’s institutional review board (protocol 09-006866,
“Development and validation of newborn screening assays
to measure biomarkers and enzyme levels in biological
samples from patients with a lysosomal storage disorder and
their relatives,” replaced by protocol 15-005393, “Develop-
ment and validation of clinical biochemical genetic assays
associated with inborn errors of metabolism and other
heritable or congenital conditions using biospecimens col-
lected from affected patients and their immediate family
members”), the Biochemical Genetics Laboratory actively
seeks parental permission to retrieve and analyze retro-
spectively the original newborn screening card of all new cases
we diagnose clinically as a combination of biochemical and
molecular tests, a situation we encounter fairly frequently,
being a worldwide referral laboratory. A total of 86 cases
have been enrolled. Twelve presumed true positives and all
but one of the presumed false positives were identified
through a National Institute of Child Health and Human
Development–funded pilot study of 100,000 anonymized
specimens from the California Department of Public Health
(HHSN275201000017C, principal investigator Dietrich
Matern, unpublished data) By the end of the first year of
prospective testing, the counts were as follows: Krabbe disease
N = 11, false-positive GALC N = 61, Pompe disease N = 40,
false-positive GAA N = 75, MPS I N = 6, false-positive
IDUA N = 99.
Study population and analytical methods
A total of 55,161 Kentucky specimens were received at Mayo
Clinic between 17 February 2016 and 18 February 2017. For
most cases, a full spot was separated from the original
card at the same time as testing was initiated locally. Batches
were shipped 6 days per week by overnight service. Residual
samples were returned after testing was completed. Six
enzyme activities were measured simultaneously by flow-
infusion tandem mass spectrometry (six-(multi)plex assay) as
recently described.19 When a repeat analysis was indicated
to investigate an initial abnormal result, the concentrations
of C20–C26 lysophosphatidylcholines were also measured
(cumulative 10-plex assay).19 Enzyme substrates were pur-
chased from PerkinElmer Life Sciences (Shelton, CT).20
Testing showed adequate stability and reproducibility over
time (coefficient of variation range: 7–15%; Supplementary
Figure 2). Two of the biochemical methods used for second-
tier tests (Krabbe disease: psychosine concentration, MPS I:
dermatan sulfate and heparan sulfate concentrations) have
been described previously.21,22 A second-tier test for the
evaluation of low GAA activity was developed during this
study and has been described separately.23 It is based on a
12-plex panel inclusive of creatine and creatinine, utilized to
calculate the (creatine/creatinine)/GAA ratio that is incorpo-
rated in expanded CLIR tools. Molecular testing of the GALC
common 30-kb deletion and Sanger sequencing of the GALC,
IDUA, and GAA genes were performed using clinically
available tests.
Multivariate pattern recognition software
Collaborative Laboratory Integrated Reports (CLIR; https://
clir.mayo.edu) is a Web application that maintains an
interactive database of laboratory results from multiple sites.
CLIR was originally developed to support Region 4 Stork
(https://www.clir-r4s.org/), a collaborative project that started
in 2004, aiming at performance improvement of newborn
screening by tandem mass spectrometry.24 In that project
cumulative reference intervals of amino acids and acylcarni-
tines were used to create postanalytical interpretive tools,25,26
which integrate all informative results into a single score and
compare it to known confirmed cases to return a percentile
ranking as a measure of likelihood of disease. The tools are
applicable to either the diagnosis of one condition or, like the
dual scatter plots described in this report, to the differential
diagnosis between two conditions with overlapping pheno-
types (i.e., true positives versus false positives).25,27 Briefly, in
the dual scatter plot the relationship to reference ranges
becomes irrelevant as the comparison now takes place
between two disease ranges. The dual scatter plot is also the
combination of two tools, one that targets any nonoverlap-
ping result to increase the score for the first condition and
decrease the score for the second one, and another that
operates in exactly the opposite way. A result within the
overlap range triggers no score variation for either condition;
a result above the overlap range increases the score of the first
tool and has the opposite effect on the second tool. A result
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below the overlap range operates in the opposite way. So, a
completely normal result could actually provide information
that would help to achieve the desired differential diagnosis,
even if the same result would not trigger any score in a one-
condition tool for either condition. Another characteristic of
the dual scatter plot is a different way to express the calculated
scores. Instead of absolute values, both axes use a process of
normalization that keeps the scores between 0 and 100. Each
result is calculated by subtracting from the score the lowest of
all scores, dividing the result by the range of values (highest
minus lowest), and then multiplying by 100. This formula
preserves the relative distance between values and is ideal for
achieving consistency among tools comparing any two
conditions with different numbers of informative markers.
The output of the dual scatter plot is a visual separation of the
combined scores in four quadrants. The lower right quadrant
includes the cluster of cases with the first condition, those
with a high score using one tool and a low score with the
other. The upper left quadrant includes the scores of cases
with the second condition. A score located in the upper right
quadrant is equivalent to an inconclusive result, meaning that
both conditions are still possible. Finally, a score in the left
bottom quadrant excludes both conditions. When used to
investigate an unknown case, the coordinates of the combined
scores of a particular case are shown as a red diamond.
CLIR’s defining characteristics are (i) the replacement of
analyte cutoff values with condition-specific degree of overlap
between cumulative reference and disease ranges, and (ii) the
integration of primary markers with all informative permuta-
tions of ratios.24 Ratios calculated between markers not
directly related at the biochemical level are particularly helpful
in correcting for preanalytical factors and potential analytical
bias. An additional and unique feature of CLIR is the
replacement of conventional reference intervals with contin-
uous, covariate-adjusted, moving percentiles.28 Utilization of
CLIR is freely available to qualified users worldwide willing to
share reference data and profiles of positive cases in advance
of being given access, with the goal of sustaining a constantly
evolving, and improving, clinical validation. Code access,
however, is not provided to external users.
Covariate adjustment
All lysosomal enzyme activities exhibited marked variation
across two continuous covariates within the newborn
population: age at collection and birth weight. To incorporate
this variation into routine data analysis, a statistical normal-
ization technique was conducted using a regression-based
method.28 This process resulted in a transformation that
could be applied to the entire (55,161) Kentucky specimen
population. Reference data from multiple contributing
labs were analyzed for homogeneity (see Supplementary
Figure 1), and if within a bias criterion based on biological
variation,28 they were integrated into a cumulative data set
binned across the covariate range to elicit any trend. If
necessary, the marker and/or covariate values were adapted
using a Box–Cox power transformation.29 Median and
standard-deviation estimates of each bin were then calculated
and polynomial regression models were fit to both of the
binned estimates. From these, Z-scores were calculated for all
reference data and prospective cases data to normalize marker
values across the entire covariate range. An example of a
regression model for the GALC enzyme and birth weight as
covariate is shown in Supplementary Figure 3. Based on the
resulting changes in degree of overlap between reference and
disease ranges in both populations, true positives and false
positives, tools were created using the adjustment for the
single covariate that overall showed a greater separation for
true positives and a greater overlap for false positives. The
chosen single covariate adjustments for GAA, GALC, and
IDUA were age, birth weight, and age, respectively.
RESULTS
The ranges of residual enzyme activities in true- and
false-positive cases for lysosomal disorders overlap almost
completely, even after covariate adjustment (Supplementary
Figure 1). A detailed comparison of three enzyme acti-
vities (GALC, GAA, and IDUA) in true-positive and
false-positive cases is presented in Supplementary Figures 4
and 5. Based on such evidence, a postanalytical interpretive
workflow (Figure 1) was implemented prospectively after
February 2016 to deliver newborn screening for Krabbe
disease, MPS I, and Pompe disease. To minimize the risk of
overlooking affected cases, the 6-plex primary screening was
set to resolve as negative only cases with a completely normal
profile, i.e., all potentially informative markers were within
the 1–99% percentile of the respective reference range.24 If an
affected patient was to be found later by clinical ascertainment
among the cases reported as screen negative, it would
represent a true false-negative event.30 The single-condition
tools identified as positive 181, 76, and 397 cases for Krabbe
disease, MPS I, and Pompe disease, respectively (Figure 1).
The dual scatter plot, a previously reported instrument of
differential diagnosis,25 was the next step of the workflow
designed to accomplish a segregation between potential true-
positive and false-positive cases. These tools assigned either
“not informative” or “artifact” status to 642 (98%) of the cases
picked up initially, leaving only 12 cases requiring further
laboratory evaluation of the initial blood-spot specimen. If no
further testing was done by repeat analysis and second-tier
tests, the false-positive rate would have been 0.01% (8/55,161)
and the positive predictive value 33% (4/12).
Repeat analysis with the extended 10-plex assay integrated
with second-tier tests resolved eight of the remaining cases as
false positives (Table 1), with one exception, described below.
Figure 2 shows the dual scatter plots (based on either 6 or 10
markers) for the differential diagnosis between Krabbe disease
and confirmed false-positive cases. The particular case
displayed in this plot shows an indeterminate outcome25 by
6-plex assay, that improves in determinacy to “consistent with
Krabbe disease” by 10-plex assay, forming an illustrative
example of the incremental value of adding more markers. As
a cautionary validation measure, laboratory directors had the
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discretion to override a not informative resolution by the dual
scatter plot and proceed with repeat testing and/or second-tier
testing (Table 1), but no discrepancies were observed. 982
samples of this cohort (Supplementary Figure 1) revealed a
profile in which more than one of the six enzyme activities
tested abnormally low, presumably resulting from preana-
lytical interferences during sample collection, handling, and/
or transport. An added benefit of the 6-plex assay was the
ability it afforded to recognize these preanalytical artifacts.
even when only a single activity among the three primary
targets was low. All cases with a profile showing two or more
low enzyme activities were deemed of no clinical relevance
and reported as screen negative after verification using
dedicated dual scatter plots between a given condition and
the cases previously classified as artifacts, which were added
to the database on a weekly basis.
Abnormal cases
Table 2 summarizes the demographic information, results,
and genotypes of the five cases reported as abnormal. Patient
2 was an exception made to our protocol: a referral was
initiated because of very low IDUA activity, despite normal
55,161
newborns
All scores = 0
(N=54,507)
Score > 0 for
Krabbe disease
(N=181)
Not informative
score
(N = 642)
Informative for
Krabbe disease
(N = 4)
Not informative
score and/or
negative second-
tier test (N = 8)
Repeat
analysis with 10-plex assay
+ second-tier tests
(4)(1)
(7)
(1)
Abnormal for
Krabbe disease
(N = 1)
Abnormal for
Mucopolysaccharidosis
type I (N = 1)
Abnormal for
Pompe disease
(N = 2)
Informative for
Mucopolysaccharidosis
type I (N = 3)
Informative for
Pompe disease
(N = 5)
Score > 0 for
Mucopolysaccharidosis
type I (N=76)
Score > 0 for
Pompe disease
(N=397)
CLIR
dual scatter plot
tool
First-tier
6-plex assay
CLIR
single-condition
tool
Genotyping
SCREENING
NEGATIVE
(N=55,156)
SCREENING
POSITIVE
(N = 5)
FALSE
POSITIVE
(N = 1)
TRUE
POSITIVE
(N = 4)
Figure 1 Analytical and postanalytical interpretive workflow of prospective screening for three lysosomal disorders. CLIR, Collaborative
Laboratory Integrated Reports; plex, multiplex assay.
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concentrations of dermatan sulfate (Table 2) measured by the
second-tier test. A repeat sample was requested and showed
again low IDUA activity and a normal second-tier test.
Clinical evaluation still ensued and included genotyping,
revealing heterozygosity for a known pathogenic variant
(Table 2). Even if no further steps were taken, the fact that
additional contact with the patient had occurred to collect a
repeat sample meets the designation of a false-positive case.31
On the other hand, the prospective screening of a full sibling
of the patient behind the legislative mandate in Kentucky,
who was diagnosed prenatally to be a carrier for Krabbe
disease, was correctly reported as screen-negative.
In terms of outcome, the case diagnosed with MPS I
received a bone-marrow transplant at approximately 6 months
of age. The two Pompe cases are evaluated every 3 months at
the University of Kentucky in Lexington. While asympto-
matic, neither is receiving enzyme replacement therapy
and testing of siblings revealed in one family an older sister
with the same genotype, clinically asymptomatic. Patient 4
exemplifies what may be construed as the ideal scenario of
newborn screening for Krabbe disease, a condition where
timely intervention is the key to achieve the best possible
outcome.16 Despite transfer of the blood-spot sample at the
beginning of a weekend, all testing was completed by the
following Monday morning and the patient was admitted to
Duke University Medical Center (Durham, NC) early on
Tuesday morning, day 7 of life. His confirmatory workup was
completed rapidly and a bone-marrow transplant took place
on day 24 of life. The patient was developing normally as of
9 months of age but with some complications, attributed to
the transplant itself.
DISCUSSION
We report for the first time that automated integration of
covariate-adjusted reference intervals and population results
combined with second-tier tests can improve the false-
positive rate of newborn screening for lysosomal disorders
to a sustainable, near-zero level. An additional novel element
of this work is the curation of condition ranges for false-
positive cases with heterozygous or pseudo-deficiency geno-
types. False-positive cases are actually a precious resource
available to pave the way to an objective, evidence-based
segregation from affected patients using CLIR tools and
second-tier tests instead of the traditional approach, employ-
ing one condition-one marker and the use of arbitrary cutoff
values,32 which is not adequate for lysosomal disorders. The
workflow proposed here resolved 98% of the cases with an
Table 1 Count of cases requiring a repeat analysis and/or second-tier tests
Krabbe disease MPS I Pompe disease Combined
Cases requiring a repeat analysis and a second-tier testa 11 57 15 83
Cases informative by repeat analysis and/or by second-tier test and reported
as screen positive
1 2 2b 5
Confirmed true positives 1 1 2 4
Confirmed false positives 0 1c 0 1
Detection rate 1:55,161 1:55,161 1:27,581 1:13,791
False-positive rate 0% 0.0018% 0% 0.0018%
Positive predictive value 100% 50% 100% 80%
MPS I, mucopolysaccharidosis type I.
aCounts include additional cases where a noninformative resolution by the 6-plex dual scatter plot was overruled for sensitivity verification purposes. bOne Pompe case
was reported as screen-positive before the second-tier test became available. cSee text for details.
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Figure 2 Dual scatter plots for the differential diagnosis between
Krabbe disease and false-positive cases. (a) 6-plex dual scatter plot;
(b) 10-plex dual scatter plot. Each plot is divided into four quadrants.
Lower right: consistent with Krabbe disease (light blue squares and
circles); upper right: indeterminate (both conditions are possible); upper
left: consistent with false-positive cases (purple squares and circles); lower
left: neither condition. Red diamonds indicate the score of one confirmed
Krabbe patient not diagnosed as part of this study. Educational material
describing the principle of a min-max score and the creation and use of
this tool is available online.40 FP GALC, false-positive result for
galactocerebrosidase deficiency.
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initial tool score greater than zero. For the sake of argument,
dismissal of marginally abnormal results as clinically
irrelevant may raise concerns about harboring false-negative
events in the population studied. While only continued
clinical surveillance could answer this question with con-
fidence, extensive precautionary measures were in place.
Foremost among them was the use of all possible permuta-
tions of calculated ratios to define a unique biochemical
fingerprint of true and false-positive cases that are recogniz-
able and separable by the software. Subjective escalation to the
10-plex panel and liberal utilization of the second-tier tests
produced no additional benefit. On the other hand,
perceivable limitations of the proposed approach are the
higher reagent cost of the 6-plex profile as primary screening,
instead of a repeat analysis; the reluctance to forsake cutoff
values and break away from established procedures, as often
happens in diverse medical fields,33 and an anecdotal concern
that results matched to four covariates may breach anonymi-
zation and therefore data could not be shared without
infringement of existing policies. Furthermore, daily public-
health practice cannot depend on manual data entry. The
automated creation of.csv files from diverse commercial
laboratory information systems now inclusive of covariates,
often extracted from separate databases, is still a challenge
that has not been adequately resolved by commonly used
platforms and requires further development.
Although the pretransplant evaluation of patient 4 was
state-of-the-art and inherently expensive, it was fully justified
by the circumstances. On the other hand, similar or even
partial workups of false-positive cases should be a source of
concern, but the financial impact of current practices is
seldom discussed. One author (D.S.P.) recapitulated the
charges actually billed to health insurance plans on behalf
of patients with whom she personally interacted while
working in a state offering newborn screening for lysosomal
disorders.12 This review showed that just the initial encounter
to work up an abnormal referral could cost an average of
$6,823 per case (range $4,242–13,438, N = 10) for the
combined expenses of office visits, counseling, procedures,
laboratory tests, and comprehensive molecular genetic testing.
A linear extrapolation of these charges to a hypothetical
nationwide implementation (~4.2 million births) when the
false-positive rate is not better than a 0.1-0.5% range may
translate into $28–143 million of unnecessary expenses per
year. Even a smaller portion of these costs would add up to
significant expenditures when applied broadly to all other
conditions with obligatory genotyping and a record of
suboptimal performance.34
With our proposed workflow, a given program has full
control of what conditions are targeted and incidental
findings can safely be avoided. In other words, a patient with
Fabry disease, Gaucher disease, or Niemann-Pick A and B
diseases will not be recognized by deploying tools for Krabbe
disease, MPS I, and Pompe disease. Screening for more
lysosomal disorders, as already mandated by a few states,
merely involves activating the tool for the additional
condition(s) of interest. The inclusion of X-linked adreno-
leukodystrophy could be accomplished by switching the
primary 6-plex screening to the 10-plex mode.19
Work is in progress to create even more complex regression
models that simultaneously correct for two continuous
covariates (age and birth weight), one categorical covariate
(sex), and location. This type of statistical modeling will
require big data,35 and a readiness to evaluate the concept that
covariate-adjusted reference intervals could be defined by
“recycling” vast amounts of normal clinical test results from
multiple sources.28 Once a critical mass of data is reached,
two-dimensional percentiles of reference and disease intervals
Table 2 Demographic information, results, and genotypes of five cases referred as abnormal over a 1-year period
Case Age at BW Sex Enzyme activitiesa Second-tier tests Genotype and corresponding
protein changeb
Case resolution
Collection Referral GAA GALC IDUA Allele 1 Allele 2
(hours) (days) (g) nmol/ml/hour
1 58 7 3,410 Male 12.60 4.20 0.20 Dermatan sulfatea
268
Heparan sulfatea
106
c.1205G>A
p.Trp402*
c.1475G>C
p.Arg492Pro
MPS I
2 42 7 2,625 Male 14.40 3.80 0.81 Dermatan sulfate
114
Heparan sulfate
35
c.713T>A
p.Leu238Gln
Wild type False-positive IDUA
3 97 10 3,366 Male 0.98 4.90 9.26 Not performed c.2238G>C
p.Trp746Cys
c.-32-13T>G Pompe disease
4 25 6 3,320 Male 15.17 0.18 6.27 Psychosinea
61
30 kb − /− a
c.1884dupA
p.Trp629Metfs*9
c.753-3462_922del Krabbe disease
5 24 4 3,544 Female 1.71 5.22 12.85 (Cre/Crn)/GAAc
4.41
c.-32-13T>G c.-32-13T>G Pompe disease
− /− indicates no deletion detected; GAA, acid α-glucosidase; IDUA, α-L-iduronidase; MPS I, mucopolysaccharidosis type I.
aUnadjusted values. The first percentile values of this study population (N = 55,161) are as follows: GAA 5.5 nmol/ml/hour; GALC 1.84 nmol/ml/hour; IDUA 3.87 nmol/
ml/hour. Bold underscored values of second-tier tests are abnormal. For ages less than 2 weeks dermatan sulfate is abnormal > 200 nmol/liter; heparan sulfate
> 96 nmol/liter; psychosine > 10 nmol/liter. bNational Center for Biotechnology Information reference sequence: GAA—transcript number NM_000152.3; GALC—tran-
script number NM_000153.3; IDUA—transcript number NM_000203.3. Protein change is shown below the genotype, when applicable. cThe 99th percentile of this ratio
in the reference population (N = 1,896) is 1.1, see ref. 23.
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in a three-dimensional space will become routinely available
as the foundation of the next generation of postanalytical
interpretive tools. At the same time, it will also be feasible to
explore their clinical applicability to a much broader
landscape of laboratory tests and panels. It is worth
mentioning that CLIR is a collaborative forum and not a
commercial product, access is freely available to legitimate
newborn screening programs and other laboratories, with the
sole requirement of sustained collaboration and data sharing
to the benefit of all users.
At a time when clinical practice is pressed to reinvent itself
through utilization management and precision-medicine initia-
tives, public health, and specifically the performance of newborn
screening, should not be exempted from public scrutiny.32,36
Newborn screening is based on laboratory tests performed on a
growing proportion of ~ 130 millions of newborns worldwide
every year. Poor performance on a mass scale distresses a
multitude of patients37 and exposes their families and providers
to high risk of psychosocial harm.38 In the case of lysosomal
disorders, genomic medicine has struggled to bring closure to
the evaluation of presumptive positive cases with an abundance
of inconclusive molecular results.34,39 In the United States, the
financial costs of open-ended monitoring of these patients could
eventually add up to hundreds of millions of dollars per year. As
status quo performance is neither scalable nor sustainable in our
health-care system, integrated biochemical phenotyping offers
an opportunity to reach the goal of meaningful delivery of
precision medicine. After 50 years of preparation,1 the era of
precision screening could start now.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the
paper at http://www.nature.com/gim
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